Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma

Published:2022-12-28 Issue:5 Volume:89 Page:1640-1655
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Dosne Anne‐Gaelle¹^ORCID,Li Xia¹,Luo Man Melody²,Nnane Ivo²,Dimopoulos Meletios A.³,Terpos Evangelos³,Sonneveld Pieter⁴,Kampfenkel Tobias⁵,Carson Robin⁶,Amin Himal⁷,Perez Ruixo Juan⁸,Zhou Honghui²⁹,Sun Yu‐Nien²¹⁰,Xu Yan²¹¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics Janssen Research & Development, LLC Beerse Belgium

2. Clinical Pharmacology and Pharmacometrics Janssen Research & Development, LLC Spring House Pennsylvania USA

3. National and Kapodistrian University of Athens Athens Greece

4. Erasmus University Medical Center Cancer Institute Rotterdam The Netherlands

5. Janssen Research & Development, LLC Leiden The Netherlands

6. Janssen Research & Development, LLC Spring House Pennsylvania USA

7. Janssen Research & Development, LLC Raritan New Jersey USA

8. Janssen‐Cilag Spain, Part of Janssen Pharmaceutical Companies Madrid Spain

9. Kira Pharmaceuticals Cambridge Massachusetts USA

10. Cognigen Division Simulations‐Plus Company Buffalo New York USA

11. Simcere Pharmaceuticals Cambridge Massachusetts USA